Opinion|Videos|December 3, 2024
Evaluating Cough Relief With Oral Nalbuphine in Patients With IPF
Author(s)Steven D. Nathan, MD
Key Takeaways
- The study focused on assessing oral nalbuphine extended release for cough relief in idiopathic pulmonary fibrosis patients.
- A randomized, double-blind, placebo-controlled trial design was employed to ensure robust and unbiased results.
Steven Nathan, MD, discusses the abstract “Analysis of Relief-of-Cough in Patients With Idiopathic Pulmonary Fibrosis Treated With Oral Nalbuphine Extended Release,” which aimed to assess the effectiveness of oral nalbuphine extended release in providing relief from chronic cough in patients with IPF; the study used a clinical trial design to evaluate cough severity, with results showing that nalbuphine significantly reduced cough frequency and intensity, offering a potential new treatment option for managing this common and debilitating symptom of IPF.
Advertisement
Episodes in this series
- Briefly describe the abstract “Analysis of Relief-of-Cough in Patients With Idiopathic Pulmonary Fibrosis Treated With Oral Nalbuphine Extended Release.”
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Advertisement
Related to this article
A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.
Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.
Young adults with cancer symptoms often fall outside screening guidelines, face costly imaging, and go undiagnosed longer, oncologists say.
Eosinophil thresholds and documentation rules shape COPD biologic access. At ERS 2026, experts discussed biomarkers, delays, and multidisciplinary care.
Oncology leaders discuss where AI delivers value, who bears liability, data readiness, and why humans must stay in the loop for clinical decisions.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
Oncology leaders say clinical pathways must shift from static documents to tools that use patient-reported outcomes and AI to guide care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
IVF Beats IUI for Early Live Births in Unexplained Infertility
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5